The Food and Drug Administration (FDA) has posted a discontinuation notice for Aerospan (flunisolide; Meda) inhalation aerosol 80mcg strength. 

Aerospan, an orally inhaled corticosteroid, is indicated for the maintenance treatment of asthma as prophylactic therapy in adults and pediatric patients 6 years of age and older. The Company stated the discontinuation was a business decision and not related to the product’s quality, safety or efficacy. 

Related Articles

Both the 60- and 120-actuation sizes have been discontinued.

For more information call (800) RX-MYLAN or visit